Safety Study of Farletuzumab, Carboplatin and Pegylated Liposomal Doxorubicin (PLD) to Treat Platinum-sensitive Ovarian Cancer

• Status: Completed
• Trial end date: 2012-10-01

Summary

The purpose of this study is to evaluate whether combination therapy with farletuzumab (MORAb-003), carboplatin, and pegylated liposomal doxorubicin (PLD) is safe.

• Phase: Phase 1

Details

• Lead Sponsor: Morphotek
• Treatments: Carboplatin; Doxorubicin; Farletuzumab; Liposomal doxorubicin